Filing Analysis
Artiva Biotherapeutics (ARTV) filed an 8-K on May 19, 2026 disclosing multiple simultaneous leadership changes effective May 18, 2026. CFO Thad Huston is departing effective May 22, 2026, with no replacement identified yet, while CEO Fred Aslan has been appointed as interim principal financial and accounting officer. Concurrently, Diego Miralles, M.D. resigned from the Board of Directors to assume the newly created role of President and Head of Research and Development.
🚩 Red Flags
- CFO departure with no successor identified — CEO serving as interim CFO/PAO creates governance and internal control risk for a clinical-stage biotech
- Multiple simultaneous executive changes (CFO out, President title reshuffled, new President/Head of R&D appointed) suggest organizational instability
- Miralles prior consulting relationship (April–May 2026) terminated immediately upon full-time hire raises questions about independence of the appointment process
- Board size reduced from 8 to 7 concurrent with the leadership reshuffling, reducing oversight capacity
- CEO dual-hatting as CFO is unusual for a Nasdaq-listed company and may raise concerns with institutional investors and auditors around segregation of duties
- Huston severance conditioned on non-revocation clause — implies potential legal risk if agreement is revoked within the 21-day window
📋 Key Facts
- CFO Thad Huston separating from the Company effective May 22, 2026; no replacement named — active CFO search underway
- CEO Fred Aslan, M.D. appointed as interim principal financial officer and principal accounting officer in addition to his CEO role
- Dr. Fred Aslan also resigned as President of the Company (a title he previously held) but retains CEO role and Board seat
- Diego Miralles, M.D. resigned from the Board of Directors (reducing board size from 8 to 7) and appointed President and Head of Research and Development
- Huston severance: ~$135,000 (3 months base salary) plus up to 9 months COBRA, conditioned on non-revocation within 21 days of Separation Date
- Miralles Offer Letter: $600,000 annual base salary, 45% target bonus, 232,500 stock options + 77,500 RSUs as inducement grants under 2025 Inducement Plan
- Miralles equity vests over 4 years: 25% on May 15, 2027, remainder over 3 years; granted under Nasdaq Rule 5635(c)(4) inducement exception
- Miralles had a prior consulting agreement with the Company (entered April 2026) that was terminated May 17, 2026 upon his full-time appointment
- Company is an emerging growth company listed on Nasdaq Global Market
- All departures stated as not resulting from disputes or disagreements with the Company
Artiva Biotherapeutics entered into an underwriting agreement to raise approximately $300 million through a public offering of common stock and pre-funded warrants. The company is issuing over 23.8 million shares and 2.1 million warrants to a group of underwriters led by Jefferies and Cantor Fitzgerald.
🚩 Red Flags
- Significant dilution to existing shareholders from the issuance of approximately 26 million new share equivalents.
📋 Key Facts
- Agreement to sell 23,871,526 shares of common stock at $11.52 per share.
- Agreement to sell 2,170,138 pre-funded warrants at $11.5199 per warrant with an exercise price of $0.0001.
- Total expected gross proceeds are approximately $300.0 million before expenses.
- Underwriters include Jefferies LLC, TD Securities (USA) LLC, and Cantor Fitzgerald & Co.
- The offering is expected to close on May 11, 2026.
- The offering was made pursuant to an effective registration statement on Form S-3 (File No. 333-289325).
Artiva Biotherapeutics announced positive initial Phase 2a clinical data for its lead candidate AlloNK in refractory rheumatoid arthritis (RA) and reached alignment with the FDA on a single Phase 3 registrational trial design. Concurrently, the company suspended its at-the-market (ATM) sales agreement with Leerink Partners.
🚩 Red Flags
- The timeline to a potential BLA submission is long, targeted for 2029.
- The current efficacy data is based on a very small sample size (13 patients with 6-month follow-up).
- Suspension of an ATM agreement often precedes a larger, dilutive underwritten public offering following positive news.
📋 Key Facts
- Reported a 50% ACR50 response rate at six months in refractory RA patients (n=13) who failed two or more prior biologic/targeted therapies.
- FDA aligned on a single Phase 3 registrational trial design involving approximately 150 patients with a 2:1 randomization.
- No instances of cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) were reported in the safety dataset.
- Suspended the Sales Agreement with Leerink Partners LLC, effectively halting ATM equity sales for the time being.
- Phase 3 trial initiation is expected in H2 2026, with primary efficacy data in H2 2028 and a potential BLA submission in 2029.
- Estimated U.S. market for refractory RA patients who failed 2+ b/tsDMARDs is 150,000 to 200,000 patients.
Artiva Biotherapeutics, Inc. announced its financial results for the fiscal year ended December 31, 2025, via a press release on March 10, 2026.
📋 Key Facts
- The filing reports financial results for the full year ended December 31, 2025.
- The announcement was made under Item 2.02 (Results of Operations and Financial Condition).
- A press release detailing the results is included as Exhibit 99.1.
- The company is classified as an emerging growth company.
Artiva Biotherapeutics has appointed Thad Huston as Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer, effective February 18, 2026. Mr. Huston brings over 30 years of experience from major biotech and pharma companies, including Galapagos NV and Kite Pharma.
📋 Key Facts
- Thad Huston (age 56) appointed as CFO effective February 18, 2026.
- Annual base salary set at $540,000 with a discretionary annual cash bonus target of 40%.
- Granted 220,000 restricted stock units (RSUs) as an inducement award, vesting over four years.
- Huston previously served as CFO and COO at Galapagos NV (2023-2025) and VP of Finance at Kite Pharma (2021-2023).
- Severance package includes 9 months of salary and COBRA for non-change-of-control termination, increasing to 12 months plus full bonus and 100% equity acceleration upon a change of control.
Artiva Biotherapeutics appointed Elaine Sorg as a Class I director effective February 18, 2026, with her term expiring at the 2028 annual meeting. Ms. Sorg is a veteran pharmaceutical executive with 35+ years of experience including senior leadership at AbbVie and Eli Lilly. This is a routine board appointment with standard non-employee director compensation.
📋 Key Facts
- Elaine Sorg appointed as Class I director on February 18, 2026, term expires at 2028 annual meeting
- 35+ years pharma experience; formerly SVP at AbbVie and President of AbbVie's U.S. commercial operations (Nov 2020 - Jan 2024)
- Currently a director of CSL Limited (global biopharma), Senior Advisor at Boston Consulting Group (since May 2024), and member of Galapagos Scientific Strategy Board (since Oct 2025)
- Annual cash retainer of $40,000 for board service
- Initial option grant of 27,500 shares (1/3 vested immediately, remainder monthly over 2 years)
- Automatic annual option grants of 13,750 shares vesting over 1 year
- All options vest in full upon a change in control
- No related-party transactions requiring disclosure under Item 404(a) of Reg S-K
- No arrangements or understandings with any person regarding her selection as director